Cassava Sciences Inc
SAVA2.235USD
+0.060+2.76%
Market hours （ET）Quotes delayed by 15 min
107.97MMarket Cap
LossP/E TTM
More Details of Cassava Sciences Inc Company
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Cassava Sciences Inc Info
Ticker SymbolSAVA
Company nameCassava Sciences Inc
IPO dateJul 14, 2000
CEOBarry (Richard J)
Number of employees30
Security typeOrdinary Share
Fiscal year-endJul 14
Address6801 N. Capital of Texas Highway
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78731
Phone15125012444
Websitehttps://www.cassavasciences.com/
Ticker SymbolSAVA
IPO dateJul 14, 2000
CEOBarry (Richard J)
Company Executives of Cassava Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Freda Nassif
Ms. Freda Nassif
Chief Business Officer
Chief Business Officer
--
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert Anderson, Jr.
Mr. Robert Anderson, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.74%
Nachtrab (Matthew)
4.69%
Barbier (Remi)
4.28%
Marshall Wace LLP
4.27%
Two Sigma Investments, LP
3.16%
Other
78.86%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.74%
Nachtrab (Matthew)
4.69%
Barbier (Remi)
4.28%
Marshall Wace LLP
4.27%
Two Sigma Investments, LP
3.16%
Other
78.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.83%
Investment Advisor
10.47%
Investment Advisor/Hedge Fund
7.36%
Hedge Fund
6.40%
Research Firm
4.19%
Venture Capital
0.18%
Bank and Trust
0.08%
Other
58.49%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
336
12.08M
25.00%
-7.63M
2025Q2
354
21.06M
43.60%
-2.49M
2025Q1
363
22.22M
46.00%
-1.56M
2024Q4
360
23.73M
49.12%
+4.41M
2024Q3
371
20.81M
43.35%
+1.72M
2024Q2
372
16.74M
35.19%
-1.63M
2024Q1
372
14.95M
34.46%
-4.56M
2023Q4
382
18.11M
42.87%
+1.40M
2023Q3
392
15.72M
37.42%
-103.08K
2023Q2
410
14.43M
34.53%
-1.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.17M
4.49%
-272.24K
-11.15%
Jun 30, 2025
Nachtrab (Matthew)
2.27M
4.69%
+2.27M
--
Aug 16, 2024
Barbier (Remi)
2.07M
4.28%
+727.36K
+54.36%
Sep 30, 2024
Two Sigma Investments, LP
1.51M
3.13%
+151.24K
+11.13%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.52M
3.15%
-1.75M
-53.57%
Jun 30, 2025
Robertson (Sanford R)
1.34M
2.78%
-5.00K
-0.37%
May 16, 2024
J.P. Morgan Securities LLC
757.06K
1.57%
+7.50K
+1.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
522.88K
1.08%
-503.72K
-49.07%
Jun 30, 2025
Barry (Richard J)
469.56K
0.97%
+117.39K
+33.33%
Mar 27, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.23%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.01%
Humankind US Stock ETF
0%
Nuveen ESG Small-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
State Street SPDR S&P Pharmaceuticals ETF
0%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.23%
iShares Micro-Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.01%
Humankind US Stock ETF
Proportion0%
Nuveen ESG Small-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
State Street SPDR S&P Pharmaceuticals ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cassava Sciences Inc?
The top five shareholders of Cassava Sciences Inc are:
The Vanguard Group, Inc. holds 2.17M shares, accounting for 4.49% of the total shares.
Nachtrab (Matthew) holds 2.27M shares, accounting for 4.69% of the total shares.
Barbier (Remi) holds 2.07M shares, accounting for 4.28% of the total shares.
Two Sigma Investments, LP holds 1.51M shares, accounting for 3.13% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.52M shares, accounting for 3.15% of the total shares.
The Vanguard Group, Inc. holds 2.17M shares, accounting for 4.49% of the total shares.
Nachtrab (Matthew) holds 2.27M shares, accounting for 4.69% of the total shares.
Barbier (Remi) holds 2.07M shares, accounting for 4.28% of the total shares.
Two Sigma Investments, LP holds 1.51M shares, accounting for 3.13% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.52M shares, accounting for 3.15% of the total shares.
What are the top three shareholder types of Cassava Sciences Inc?
The top three shareholder types of Cassava Sciences Inc are:
The Vanguard Group, Inc.
Nachtrab (Matthew)
Barbier (Remi)
The Vanguard Group, Inc.
Nachtrab (Matthew)
Barbier (Remi)
How many institutions hold shares of Cassava Sciences Inc (SAVA)?
As of 2025Q3, 336 institutions hold shares of Cassava Sciences Inc, with a combined market value of approximately 12.08M, accounting for 25.00% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.60%.
What is the biggest source of revenue for Cassava Sciences Inc?
In --, the -- business generated the highest revenue for Cassava Sciences Inc, amounting to -- and accounting for --% of total revenue.
